Megalestari Epack says no warrants planned in PMHMETD I rights issue
Bitget2026/10/06 13:10Megalestari Epack Sentosaraya responded to an IDX query on its planned PMHMETD I rights issue, excluding warrants or other equity securities. Rights ratio, exercise price, working-capital allocation remain undecided; final terms to be disclosed in the prospectus, based on market conditions. Pro forma assumes issuance of 2,000,000,000 new shares at Rp 50 par, lifting paid-up capital to 5,303,400,000 shares. No standby buyer has been appointed for the PMHMETD plan. Buyback proposal filed near the rights issue is separate; buyback would use internal excess funds, not PMHMETD proceeds. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PT Megalestari Epack Sentosaraya Tbk published the original content used to generate this news brief via Indonesia Stock Exchange (IDX) (Ref. ID: 32163942) on October 06, 2026, and is solely responsible for the information contained therein.
- Megalestari Epack Sentosaraya responded to an IDX query on its planned PMHMETD I rights issue, excluding warrants or other equity securities.
- Rights ratio, exercise price, working-capital allocation remain undecided; final terms to be disclosed in the prospectus, based on market conditions.
- Pro forma assumes issuance of 2,000,000,000 new shares at Rp 50 par, lifting paid-up capital to 5,303,400,000 shares.
- No standby buyer has been appointed for the PMHMETD plan.
- Buyback proposal filed near the rights issue is separate; buyback would use internal excess funds, not PMHMETD proceeds.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
Crypto prices
More
